ANDOVER,
Mass., Feb. 12, 2024 /PRNewswire/
-- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a
medical technology company that is transforming organ transplant
therapy for patients with end-stage lung, heart and liver failure,
today announced that it will release financial results for the
fourth quarter and full year 2023 after market close on
Monday, February 26, 2024. The
TransMedics management team will host a corresponding conference
call beginning at 4:30 p.m. ET /
1:30 p.m. PT.
Investors interested in listening to the conference call may do
so by dialing (866) 807-9684 for domestic callers or (412) 317-5415
for international callers and ask to be joined into the TransMedics
call. A live and archived webcast of the event will be available on
the "Investors" section of the TransMedics website at
https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the
world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian
Johnston
332-895-3222
Investors@transmedics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-fourth-quarter-and-full-year-2023-financial-results-on-february-26-2024-302059630.html
SOURCE TransMedics Group, Inc.